clouds leave no trace

High Cloud Quintet w/ mentions of the Trailblazer (gn!trailblazer pov)

warnings: spoilers if you haven’t done the Xianzhou Luofu main story

word count: 1.7k

a/n: this wasn’t planned, the words just came to me, hope yall like it, not beta read hcq means so much to me help

description: high cloud quintet romanticized (lore), a quick recap from Jing Yuan’s pov – basically poetic analysis of hcq history through Jing Yuan’s eyes (fluff, angst)

if you think Jing Yuan didn't love Blade think again. he is the youngest of the high cloud quintet, he grew up beside them- he loved them all. and they all adored him as well. to say he didn't care about Yingxing is ignorant. because he loved the arrogant short-life species swordsmith. he got older knowing he might outlive him, knowing he will watch him grow old, the way he'd cling onto him and use every moment to be beside him. in his home or Yingxing’s home he'd hold him in his arms, always giving him a back hug and chatting. as he would with Dan Feng, their fingers intertwining in a gentle intimate touch, he would hold him as well. the strict, stubborn high elder softening up once they all warmed up to each other. oh, the way Dan Feng would walk at a seemingly calm, fast pace to the young Jing Yuan's home for a moment, just a minute of peace, of tranquility. the high elder would draw his fingers through the long white hair, maybe even make a braid or two. he'd kiss Jing Yuan's temple and mumble how much comfort he gave him.

the three are so soft behind closed doors. and when the high cloud quintet would gather to drink and share stories, a rare occurrence, since they're usually on the battlefield, Baiheng and Jingliu would just smile; one's head on the other's shoulder at the sight of the arrogant craftsman, the stubborn high elder, and strategic cloud knight smiling at each other.

just like Jingliu would lean to kiss Baiheng's cheek after a warm story she'd share, chuckling in joy at hearing her speak in a happy tone.

the same way the older men would gravitate to Jing Yuan, furthermore the way Jing Yuan would cling onto both of them. overlapping as they share stories and drink their fill.

so when the time would come for all of it to fall apart when one died, the second met a fate worse than death, the third one was forced to reincarnate and the new one to be imprisoned, the fourth to lose her mind, what would be of the fifth one?

of the young boy in the beginning, and the man on that day. the general. who lost it all, his friends, his lovers, his everything. he cannot even allow himself to scream and cry and angrily throw a ceramic plate on the floor otherwise he'd get marastruck. yes, fully aware of what is left for him to do but suppress all emotions. fighting that Jingliu escapes somewhere safely, making sure Yingxing is banished and not captured, making sure the same fate meets the Imbibtor Lunae reborn- to also be banished and hopefully achieve what Jing Yuan knew his previous reincarnation oh-so wanted; freedom... and making sure that what happened to Baiheng stays secret and safe, making sure that her new reincarnation is alright- going from a Foxian to a Vidyadhara- he must've been so worried. he'd check up on her often, and ask about her dreams. the easy-going smile turning down for a second when she would say she doesn't have any dreams- the hope he'd feel when she'd tell him that after visiting the Astral Express once; she dreamt of being a Foxian pilot. he'd nod with that sweet smile and turn to leave. he says he never grew close with his master, Jingliu… because it is easier to say that than admit to the reality and the pain of losing someone he cared for so much.

after the banishment and when the dust settled, long before the nameless arrived… he sits under a ginkgo tree and decides to meditate. the weight of all that history and not one of the remaining ones remembers it for what it was except for him. so he meditates, clearing his head, and calming his own memories.

so when he meets Yingxing- with his youthful appearance- where Jing Yuan remembers him with gray-white hair and lilac eyes, he is met with dirty orange-red ones and dark hair, his voice rough and raspy in comparison to what the general remembers. the sting in his heart when he sees Yingxing’s hands shake, he knows how much the fact he cannot craft anymore must hurt him. Yanqing urges the general to make the arrest, yet he lets the fugitives go. not batting an eye, there's no more love on either side, no warm emotion that used to be there. but love isn't an emotion, it is a promise. a promise to be there when it is needed. and the promise is loud when he lets... Blade and Kafka leave. there's a longing in his chest for the strong embrace of his lover when Blade turns his back to leave, and he pushes those thoughts back.

so when the trailblazer meets him and he looks so warm, the sun-bathed kind general- they can see it on him, that warmth like he was loved and that he also loved. that he was held and he also held. he'd appear so soft, cuddly, endearing.. just an aura, a mere bright shadow of what he was. just an appearance, like a shell that used to be there. ash still shining some light, unlike the warm fire that burned with love.

he is the general of the Xianzhou Luofu and that is his number one priority. he uses this leftover love which rubbed up on him as a crafty mask, a decoy for enemies of the Seat of Divine Foresight.

unprepared he walks to see the Imbibitor Lunae. in his original form. his tongue faster than his mind as he calls him Dan Feng. the small smile colored with pain when he hears the words, "I'm not him", and the grief-filled nod he offers in return. still, he uses it all to the advantage of the Luofu.

he isn't grief struck, nor mara struck, he has immense control over his emotions, but when put right in front of the man his fingers just ich to hold his hand, well of course he slips up for a second, and no longer than that. he cannot allow himself, he does not allow himself. he is never weak.

so when... Dan Heng and... Bailu walk around Luofu and go to a sacred location finding themselves in an ambush, of course, he doesn't call reinforcements- that by itself could cause more trouble. he, still injured from his fight with Phantylia, comes to aid them and fight beside them.

and of course, he hangs his head low, his bangs covering both of his eyes when a reunion after seven centuries, if one could even call it that, happens. Blade insists that Jingliu fights him. clashes of swords fill his ears, Dan Heng's shallow breathing beside him as the two of them fight until Jingliu wins. he shuts his eyes tight when Blade falls down, his body making the stone ground crack from the hit, holding his own breath to hear when Blade’s lungs rise again in his immortal body. exhaling when the man inhales. one might say Dan Heng is newly reborn and has no memories of this. yet he dreams, and like all of his species, he regains those memories through his dreams even when he tries to ignore them. he knows, he remembers… he still wears the bracers he exchanged with Yingxing. Jing Yuan regrets he cannot stop them from fighting each other, his voice shaking at the end of the gathering.

it is obvious a side of him wishes it all to go back to how it was, yet those people he knew don't exist anymore. Dan Feng was killed by Jing Yuan's tongue, Jingliu’s gone by his own spear, he watched Yingxing turn into a mindless killer and Baiheng become an Abomination. and he could do nothing about it, as they all fell apart around him like ash floating in the air after the fire had been put out. they burned so bright.

the poor general. and Blade continues to travel with the Stellaron hunters, Dan Heng hides his form and travels with the Astral Express, Jingliu goes to a prison cell – even in the end he made an effort to divert her plans of which prison to go to, Bailu keeps working as a doctor and he still comes over occasionally to check up on her, hoping she remains well in this lifetime. his past friends (and lovers) are all, as he puts it, scattered to the wind.

all the history, the memories, the hugs he won't ever get again, the soft touches, warm beds, the kind words- the harsh words, the training, the glasses of alcohol, the soft lips on his... all lost, forgotten. and with his meditation- even he remembers only fragments- perhaps only the happy ones, maybe, if they don't hurt too much as Mimi's do.

so when the trailblazer walks into the Seat of Divine Foresight they see the general of the Xianzhou Luofu, one of the seven Arbiter-Generals of the Xianzhou Alliance's Cloud Knights, one of the Six Charioteers of the Xianzhou Luofu, the Divine Foresight, the strong, incredibly smart, strategic genius and powerful Jing Yuan, and also the dozing general, they see exactly who Jing Yuan chooses himself to present as. leader of the Luofu, mentor of Yanqing, older than any general so far, in an era of peace he fought to happen. the trailblazer doesn't see the past, and what he has been through to stand there and greet them with a smile. he shines like the sun because he burns like one. never-ending, bright, warm, golden. they won't see him crack, because he won't crack. he is incredibly strong mentally and keeps his emotions in check.

with the lazy smile that everyone knows too well and the deep-toned voice he'd greet,

"ah trailblazer, I've caught some free time, would you care for a round of starchess?"

a/n: amnesic meditation is a thing on the luofu where you forget certain memories* that is what I was referring to when JY meditated- it is canon he did that to forget Mimi btw. also the “love is a promise” yes is a reference to an episode of DW whr the Doctor says that line, I loved it had to include it

Sooooo in ur authors notes of nostalgic chill u mentioned that you’d be willing to explain how Yanqing’s going thru it on ur tumblr….. mayhaps you could talk about it?

(Ur fics really good btw!! And I love all you’re art for hsr!!!)

disclaimer for those who come across this withotu reading my fic: this is a character analysis for yanqing in this fic. ignore canon. it holds no dominion here. thank you hoyoverse for the characters but ill take it from here. anyways, people say the fic is good, so consider reading?

anyways. IM SO EXCITED TO ANSWER THIS, forgive the long drabble youre about to read.

OK SO. first up standard YQ and JY.

YQ has been kept mostly in the dark about the sedition of IL, but he has a rough idea about what went down. in his head, it went like this: "something bad goes down and everyone abandons each other for self preservation."

this isnt... wholly right, but he's not entirely wrong either. the whole point is that YQ has only ever known the aftermath of the event---blade being angry and vengeful, JL being... herself, and then JY suffering almost constant heartache.

so, when he meets the younger JY, hes very... uncomfortable

not only is this version nothing like the general, hes also much happier. hes surrounded by people who YQ believes will one day abandon him entirely, causing him to spend the rest of his life grieving a group of people that never seemed to care for him as much in return. (note, this is how YQ sees it)

not only this, but seeing HCQ together makes him realise that he is closer to the general than any of the HCQ members were to JY---and devolves into a whole new crisis.

YQ has, for the past 10 or so years, been the general's closest confidant---his son, his only family, his apprentice and his best friend. knowing that he hasnt been able to make a dent in the grief left behind by people who don't appear to be more than his friends takes a large chunk out of YQ's self confidence, and he begins questioning how important he is to JY.

now, normally, YQ would bring this up with the general. but currently, thats not really possible. he tries, after losing to JL, but the more he talks to the younger JY, the more he starts seeing the JY he knows instead.

not only that, but the entire fact that he is in the past has YQ constantly on edge. he doesnt know if his actions will change the future he comes from, so having to watch this inevitable trainwreck forming around him without being able to help adds an extra layer of unease.

i was going to talk a bit about JL but i now realise i havent actually finished that chapter so were all just going to hafta wait for that!

A brand-new scientific study compared hundreds of hospitalized recipients of hydroxychloroquine (and azithromycin) with thousands of controls who received standard hospital care. Source This study was carefully done, peer-reviewed, and published in a prestigious journal. It looked at very sick, hospitalized patients with COVID-19 and tried to see if hydroxychloroquine, given with or without the antibiotic azithromycin, would help save lives. The authors selected matching controls to account for any possible confounding effects. We conducted a retrospective analysis to compare the 28-day mortality rate in 352 patients treated with hydroxychloroquine with or without azithromycin (HCQ-group) in our hospital with a contemporary control group of 3533 patients receiving standard of care from the Belgian … Continue reading →

seeing all the perspectives and analysis on the xianzhou arc/dan heng and dan feng/hcq is amazing. even if i don't agree with every perspective i see, there are so many things i'd never have considered all on my own, and it makes me value the story all the more.

― Robert F. Kennedy Jr., The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health

“In April, Dr. Vladimir (Zev) Zelenko, M.D., an upstate New York physician and early HCQ adopter, reproduced Dr. Didier Raoult’s “startling successes” by dramatically reducing expected mortalities among 800 patients Zelenko treated with the HCQ cocktail.29 By late April of 2020, US doctors were widely prescribing HCQ to patients and family members, reporting outstanding results, and taking it themselves prophylactically. In May 2020, Dr. Harvey Risch, M.D., Ph.D. published the most comprehensive study, to date, on HCQ’s efficacy against COVID. Risch is Yale University’s super-eminent Professor of Epidemiology, an illustrious world authority on the analysis of aggregate clinical data. Dr. Risch concluded that evidence is unequivocal for early and safe use of the HCQ cocktail. Dr. Risch published his work—a meta-analysis reviewing five outpatient studies—in affiliation with the Johns Hopkins Bloomberg School of Public Health in the American Journal of Epidemiology, under the urgent title, “Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients that Should be Ramped-Up Immediately as Key to Pandemic Crisis.”30 He further demonstrated, with specificity, how HCQ’s critics—largely funded by Bill Gates and Dr. Tony Fauci31—had misinterpreted, misstated, and misreported negative results by employing faulty protocols, most of which showed HCQ efficacy administered without zinc and Zithromax which were known to be helpful. But their main trick for ensuring the protocols failed was to wait until late in the disease process before administering HCQ—when it is known to be ineffective. Dr. Risch noted that evidence against HCQ used late in the course of the disease is irrelevant. While acknowledging that Dr. Didier Raoult’s powerful French studies favoring HCQ efficacy were not randomized, Risch argued that the results were, nevertheless, so stunning as to far outweigh that deficit: “The first study of HCQ + AZ [ . . . ] showed a 50-fold benefit of HCQ + AZ vs. standard of care . . . This is such an enormous difference that it cannot be ignored despite lack of randomization.”32 Risch has pointed out that the supposed need for randomized placebo-controlled trials is a shibboleth. In 2014 the Cochrane Collaboration proved in a landmark meta-analysis of 10,000 studies, that observational studies of the kind produced by Didier Raoult are equal”

As you can see, the most favored group was those who received the regimen of hydroxychloroquine and azithromycin early in the course of illness. Of the 30,202 patients for whom treatment information was available, 191/23,172 patients (0.82%) treated with HCQ-AZM died, compared to 344/7,030 patients (4.89%) who did not receive HCQ-AZM. All the other combinations received are reported in the figure.

Important points:

HCQ+AZM consistently reduced the risk of hospitalization and death

If hospitalized, those pre-treated with HCQ+AZM at home had a greater chance of survival

Critics say this was not a randomized trial. Patients say it does not matter, they just want to survive on HCQ + AZM! When the differences are this large, we go with what is working for patients, not a false narrative from the Bio-Pharmaceutical Complex deceiving the population on simple, safe, generic drugs.

COVID-19 Diagnostics

On March 11, 2020, the World Health Organization declared a global pandemic arising from corona virus disease – 19 (COVID-19). Some of the first cases that began from Wuhan (China) in end of 2019 have reached almost 4,347,935 cases causing 297,241 deaths, worldwide (As of 15 May 2020). On one hand the healthcare systems globally have been struggling to manage the COVID-19 patient population and the researchers are racing to find a solution to this problem; while on the other hand, the economic impacts are felt across other sectors. Globally, there has been GDP decline, increase in unemployment rates, and increase in inflation rates. For instance, in the U.S., by end of April 2020, more than 3.8 million people were laid off and roughly 30 million people filed for jobless aid. In the U.K., around 7.5 million people are covered under furlough scheme, a government’s job retention scheme (May 2012). Top countries to have the most number of confirmed cases (As of 15 May 2020) included the U.S., Spain, Russia, the U.K., Italy, Brazil, France, Germany, Turkey, and Iran. Top countries to have most number of deaths due to COVID-19 (as of 15 May 2020) include the U.S., the U.K., Italy, France, Spain, Brazil, Germany, Iran, Turkey, and India.

Key Players

Some of the key players involved in the COVID-19 product development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline                     

Diagnosis

PCR Testing

Antibody Testing

Treatment

Vaccines         

Immunotherapy

Antiviral

Cell-based Therapy

Other Therapies                                       

COVID-19: Impact on Healthcare Industry  

Diagnostics

Rapid Test Kits

PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests

Advantages Offered by PCR Testing in COVID -19 Diagnosis

Restraints

Key Companies

Antibody Testing / Serological Testing

Advantages Over Molecular Tests

Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down

Restraints

Key Companies

Therapies

Vaccines

Immunotherapies (Antibodies)

Monoclonal Antibody

T-Cell Therapy

Potential Game Changers: Antibodies

Ilaris (Canakinumab)

Sylvant (Siltuximab)

Lenzilumab

Ultomiris (Ravulizumab-Cwvz)

Tocilizumab

Anti-Virals

Potential Game Changers

Chloroquine and Hydroxychloroquine (HCQ)

Remdesivir

Cell-Based Therapies

Other Therapies

Plasma Therapy

Devices

COVID-19 Industry Impact Assessment, by Geography       

North America

Europe

Asia-Pacific (APAC)

Rest of the World (RoW)

𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 @https://www.meticulousresearch.com/download-sample-report/cp_id=5098?utm_source=Product&utm_medium=Social&utm_campaign=Product&utm_content=16-02-2023

COVID-19 Diagnostics

On March 11, 2020, the World Health Organization declared a global pandemic arising from corona virus disease – 19 (COVID-19). Some of the first cases that began from Wuhan (China) in end of 2019 have reached almost 4,347,935 cases causing 297,241 deaths, worldwide (As of 15 May 2020). On one hand the healthcare systems globally have been struggling to manage the COVID-19 patient population and the researchers are racing to find a solution to this problem; while on the other hand, the economic impacts are felt across other sectors. Globally, there has been GDP decline, increase in unemployment rates, and increase in inflation rates. For instance, in the U.S., by end of April 2020, more than 3.8 million people were laid off and roughly 30 million people filed for jobless aid. In the U.K., around 7.5 million people are covered under furlough scheme, a government’s job retention scheme (May 2012). Top countries to have the most number of confirmed cases (As of 15 May 2020) included the U.S., Spain, Russia, the U.K., Italy, Brazil, France, Germany, Turkey, and Iran. Top countries to have most number of deaths due to COVID-19 (as of 15 May 2020) include the U.S., the U.K., Italy, France, Spain, Brazil, Germany, Iran, Turkey, and India.

Key Players

Some of the key players involved in the COVID-19 product development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline                     

Diagnosis

PCR Testing

Antibody Testing

Treatment

Vaccines         

Immunotherapy

Antiviral

Cell-based Therapy

Other Therapies                                       

COVID-19: Impact on Healthcare Industry  

Diagnostics

Rapid Test Kits

PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests

Advantages Offered by PCR Testing in COVID -19 Diagnosis

Restraints

Key Companies

Antibody Testing / Serological Testing

Advantages Over Molecular Tests

Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down

Restraints

Key Companies

Therapies

Vaccines

Immunotherapies (Antibodies)

Monoclonal Antibody

T-Cell Therapy

Potential Game Changers: Antibodies

Ilaris (Canakinumab)

Sylvant (Siltuximab)

Lenzilumab

Ultomiris (Ravulizumab-Cwvz)

Tocilizumab

Anti-Virals

Potential Game Changers

Chloroquine and Hydroxychloroquine (HCQ)

Remdesivir

Cell-Based Therapies

Other Therapies

Plasma Therapy

Devices

COVID-19 Industry Impact Assessment, by Geography       

North America

Europe

Asia-Pacific (APAC)

Rest of the World (RoW)

𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 @https://www.meticulousresearch.com/download-sample-report/cp_id=5098?utm_source=Product&utm_medium=Social&utm_campaign=Product&utm_content=06-01-2023

Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease

New Post has been published on https://petn.ws/2CiHS

Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease

HCQ and clinically diagnosed incident ADRD in medicare claims data analyses The full study protocol for patient-level analysis in Medicare claims was pre-registered on clinicaltrials.gov prior to data analysis (NCT04691505) and contains detailed information on implementation including all codes that were used to identify study variables to allow future replication. These analyses were performed within […]

See full article at https://petn.ws/2CiHS #PetInsuranceNews

Encapsulation involving pea health proteins within an alginate matrix simply by frosty collection gelation technique and use from the supplements throughout juices.

Results All of the kinds of aPL utilised reduced your combination catalog in BeWo and primary trophoblastic cells (64%, 52%, and 41% with regard to BeWo tissue along with 67% as well as 62% regarding major cellular material, correspondingly), along with anti-2GP1 antibodies lowered hcg weight loss secretion within BeWo cellular material (41%). To block TLR4 antibodies or abolish TLR4 cellular surface area term renewed combination list in the cellular types and also -human choronic gonadotropin bodily hormone removal within BeWo tissue. HCQ treatment caused exactly the same result along with reduced TLR4 mRNA (40% as well as 35%, correspondingly) along with proteins expressions (62% as well as 42%, respectively) inside BeWo cellular material. Finish Anti-2GP1 antibodies lower trophoblastic distinction through TLR4. This particular result is refurbished through HCQ, advising their healing curiosity about APS pregnancies.All of us identify using 2-hydroxy-1,4-naphthoquinone (HNQ, Lawsone) as being a prospective sweat electrolyte dimension gun. We all utilize ultraviolet-visible absorbance sizes to discover the absorbance vitality inside a distinct wave length assortment (300 nm-500 nm). This kind of story strategy permits us to remove the need for the actual wave length with the absorbance top nevertheless discover the important from the range of attention. Though many of us numerically compute the actual absorbance power, it really is important to make use of photodiodes to determine your concentration of your carried light that is certainly created designed for all the various curiosity with regard to future unit implementations. We looked into different mixing rates water as well as acetone to find the optimum solution that could supply the the majority of sensitive as well as precise relative electrolyte sensing. The particular pH value has also been changed to view the consequence around the absorbance electricity as well as power. An associate group of topics were utilized to get perspiration from the dehydration and hyperhydration instances. The results are usually convincing which HNQ options bring a new wearable, continuous sweating sensing unit. (Chemical) 2014 AIP Publishing LLC.ObjectivesTo examine anti-proliferatory exercise of the decided on And,N-[(8-hydroxyquinoline)methyl]-substituted benzylamine (JLK1486) in most cancers tissue and to define their mechanism associated with mobile or portable human population growth inhibition Selleckchem MYK-461 . Supplies along with methodsIn vitro civilizations of B16F10 (computer mouse button melanoma) cells were chosen as being a model to characterize anti-proliferatory exercise associated with JLK1486 utilizing MTT expansion assay, trypan azure viability assessment, cellular routine analysis, melanin creation, -galactosidase along with acridine red soiling. ResultsProliferating B16F10 and also MeWo (human most cancers) tissue ended up strongly growth restricted simply by JLK1486, showing IC50 valuations of 196nm and 110nm correspondingly. Anti-proliferatory outcomes were independent of cellular dying along with were seen as an a definite accumulation associated with tissues within G(2)/G(One) cycle. Tyrosinase action as well as comparative melanin articles continued to be unchanged indicating the anti-proliferatory action has not been because of phenotype difference. Despite the fact that treated B16F10 cells tarnished clearly beneficial regarding senescence sign -galactosidase, cellular material obtained in close proximity to normal proliferatory exercise after eliminating JLK1486. Greater acridine red soiling along with presence of perinuclear vacuoles suggested induction involving autophagy within B16F10 tissue.

Can Ivermectin Be Taken For Covid?

Is Ivermectin truly reliable for Covid-19?

As well as the last verdict of the meta-analysis of key professional studies was that sometimes,Buy Ivermectin Online can function as a precautionary medicine. Its usage can assure a decrease in infection by an average of 62 %. Nonetheless, this truth has not been validated, because large regulated research studies have not been conducted. Perhaps, it will be confirmed in the future, but at the moment, Ivermectin is used only in patients with a validated medical diagnosis.

All of the data offered by clinical laboratories give confidence in the effectiveness of Ivermectin for Covid-19.

Meant mechanism of action for Covid-19.

It ought to be noted that there have been performed no thorough randomized studies on the system of Ivermectin 12Mg Buy Online activity for Covid-19. There simply had not been enough time for this. To have a clear understanding of how Ivermectin acts in reducing individual death, more time is needed. So, at the moment, all the information provided by the labs are of surface nature.

It is thought that Ivermectin manifest antiviral activity. It affects the SARS-CoV-2 infection by interaction with its RNA. It blocks the import of protein right into the infection cell, which interrupts the natural processes for the spread of the virus at the cell level. Without sufficient supply of cells with healthy protein, the development of the infection slows down as well as its pathogenicity lowers.

Furthermore, it is thought that Ivermectin blocks the web link of SARS-CoV-2 with ACE-2 receptors, which inhibits the growth of the transmittable procedure. As you understand, the SARS-CoV-2 infection prompts a serious form of lung pneumonia, which is just one of the causes of death. The use of Ivermectin can help reduce the possibility of development of an inflammatory as well as transmittable process.

For More Meds:- Ziverdo kit Online | Buy Ivermectin | Buy HCQS-200

Harvard Meta-Analysis Shows Statistically Significant Positive PrEP Effect from HCQ

Historically, medical research has often taken a one-size-fits-all approach, lumping women and men together despite growing evidence that the sexes differ in how they catch and fight disease.

A stark example was the heart drug digoxin, which was widely marketed in the late 1990s on the basis of a trial that showed it to be effective and safe. But over time a higher incidence of side-effects in women emerged. When the same dataset was analysed on the basis of sex, it showed digoxin decreased mortality in men – but increased mortality in women.

“Women are not just small men,” one expert said.

Covid-19 seems to be a case in point when it comes to differences between the sexes, with men thought to be up to twice as likely as women to die from the virus. But a new analysis suggests that scientists involved in the race to develop medical interventions for the coronavirus have paid little attention to these disparities.

In a still to be peer-reviewed study, researchers found that only 416 of the 2,484 Covid-19 clinical trials mention sex/gender as a recruitment criterion on the ClinicalTrials.gov database.

There had been just 11 original reports of randomised-controlled clinical trials published by journals in June, and none of the analyses was disaggregated by sex – although each study did report the number of female and male participants.

Some of those 11 studies evaluated hydroxychloroquine (HCQ), a decades-old malaria drug that initially generated buzz as a potential Covid-19 treatment.

HCQ causes heart rhythm side-effects that can be deadly, and the drug’s side-effects are known to be more prevalent in women, said study author Dr Sabine Oertelt-Prigione, chair of sex and gender-sensitive medicine at Radboud University in the Netherlands. If you don’t provide a sex-disaggregated analysis for a drug like this, she said, “what happens with all the potential new therapies?”

Mathias Wullum Nielsen, of the University of Copenhagen and an author of the latest analysis, said: “I think our study … suggests deeply ingrained norms that are difficult to change.”

While there is recognition today that women should be adequately represented in clinical trials, a series of birth defects and other problems resulting from foetal exposure to certain drugs between the 1940s and 1970s prompted scientists to initially exclude women and their foetuses, and later women of childbearing age, from clinical drug research.

Women were also seen as confounding test subjects, with their fluctuating hormonal levels, by researchers who generally believed that women and men would similarly respond to drugs. Eventually, Caucasian males came to be considered the “norm” population. Regulatory standards slowly shifted in favour of re-including women in trials by the 1990s.

But change came slowly, and even though researchers now typically maintain sex balance in trial recruitment, the final step of analysing data by sex does not always occur – with damning outcomes.

A 2001 study conducted by a government agency that holds US Congress to account found that of the 10 drugs that had been withdrawn from the US market since 1997, eight posed greater health risks for women than for men.

“The problem is, if you don’t do sex analysis – if males and females have very different responses – you could miss [accurate data on] everybody,” said Londa Schiebinger, a history of science professor at the University of Stanford.

Many funding agencies now require that scientists conduct sex analyses, as have some medical journals, while drug regulators are encouraging the practice. But until the exercise is enforced it appears the status quo will continue, experts said.

“People will promise anything if it allows them to either record the study or secure funding … but if it’s not being monitored, it doesn’t necessarily happen,” said Oertelt-Prigione.

“Women are not just small men. We have different hormones [levels], smaller kidneys and more fat tissue where drugs can accumulate,” said Dr Cara Tannenbaum, a scientific director at the Canadian Institutes of Health Research. “There’s so many reasons why things can go wrong.”

When it comes to Covid-19, and infectious diseases in general, female immune systems are considered stronger, in part because they have two X chromosomes that are understood to shape immune responses, although environmental factors play key roles. There are other established physiological and anatomical differences that may also make women more susceptible to some drug-related risks.

It’s therefore imperative that scientists analyse data by sex, the experts stressed.

“It’s a new virus we’re dealing with … there’s a lot of open questions,” said Oertelt-Prigione.

“Especially in a situation like this, providing data can help move mountains, and it can help convince people who usually wouldn’t think that this is a priority.”

Dr. Peter McCullough: The State of COVID Treatment

Story at-a-glance Cardiologist, internist and epidemiologist Dr. Peter McCullough discusses why a key aspect of care — early treatment — has been missing from the pandemic With no hope of early treatment, McCullough believes that most people became conditioned to wait for an injection COVID-19 injections are waning in effectiveness and linked to an unacceptable number of serious injuries and deaths McCullough is among a growing number of experts who believe COVID-19 injections are making the pandemic worse; indiscriminate vaccination is driving mutations, as the virus is mutating wildly to evade the injections At 53:40 in the video, you can view McCullough’s early treatment regimen, which initially includes a nutraceutical bundle, progressing to monoclonal antibody therapy, anti-infectives like HCQ or ivermectin, antibiotics, steroids and blood thinners

The video above,1 featuring cardiologist, internist and epidemiologist Dr. Peter McCullough, is packed with sound logic, data and action steps that have the potential to turn the pandemic around — if only more people would listen.Recorded at the Andrews University Village Church in Berrien Springs, Michigan, August 20, 2021, this presentation deserves to be heard, and I urge you to listen to it in its entirety. It will make you question why a key aspect of care — early treatment — has been missing from the pandemic.McCullough, editor of two medical journals who has published 650 peer-reviewed papers, said this has been the first time in his career when he saw medical providers not offering early treatment for a disease.Early COVID Treatment Saves Lives The standard of care for COVID-19 has been to withhold treatment until a person is sick enough to be hospitalized. It typically takes two to three weeks for someone with COVID-19 to get sick enough to be hospitalized, and during that time early treatment can be lifesaving.The rationale was that there have been no large, randomized trials conducted to know which treatments are safe and effective, but as McCullough said, "We can't wait for large randomized trials … Something got in the minds of doctors and nurses and everyone to not treat COVID-19. I couldn't stand it." He and colleagues worked feverishly to figure out a treatment — why didn't national health organizations do so also?"Our government and other governments, and the entire world, has not lifted a finger to reduce the risk of hospitalization and death anywhere," McCullough said, pointing out the irony: "If there was a kid with asthma, would we let the kid wheeze and choke for two weeks before the kid has to go to the hospital? No, we give the child medications. We don't have randomized trials for every single thing that we do."2 McCullough and colleagues realized that there are three major phases to COVID-19. It starts with virus replication, which then triggers inflammation, or a cytokine storm. This, in turn, leads to blood clotting. If enough micro blood clots form in the lungs, a person can't get enough oxygen and dies. It's a complex process, and no single drug is going to work to treat it, which is why McCullough uses a combination of drugs, as is done to treat HIV, staph and other infections.Only about 6% of doctors' decisions in cardiology are based on randomized trials. "Medicine is an art and a science, it takes judgment. What was happening is, I think out of global fear, no judgement was happening," McCullough said,3 referring to doctors' refusal to treat COVID-19 patients early on in the disease process.Doctors Threatened for Treating COVID-19 Around the world, the unthinkable is happening: Doctors are being threatened with loss of their license or even prison for trying to help their patients. French doctor Didier Raoult suggested, early on, putting up a tent to try to treat covid-19 patients. He was put on house arrest. He has promoted the use of hydroxychloroquine (HCQ), which initially was available over the counter — until France made it prescription only.4In Australia, if a doctor attempts to treat a COVID-19 patient with HCQ, they could be put in prison. "Since when does a doctor get put in prison to try to help a patient with a simple generic drug?" McCullough said. In South Africa, he added, a doctor was put in prison for prescribing ivermectin.In August 2020, McCullough's landmark paper "Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 Infection" was published online in the American Journal of Medicine.5The follow-up paper is titled "Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection (COVID-19)" and was published in Reviews in Cardiovascular Medicine in December 2020.6 It became the basis for the home treatment guide.While some physician organizations have stepped up and are treating COVID-19 patients, "The ivory tower today still is not treating

patients. The party line in my health system is, do not treat a COVID-19 patient as an outpatient. Wait for them to get sick enough to be admitted. Because my health system … follows the National Institutes of Health or the Centers for Disease Control, period." Conditioned to Wait for an Injection With no hope of early treatment, McCullough believes that most people became conditioned to wait for an injection. "We became conditioned, after about May or so, to wear a mask, wait in isolation and be saved by the vaccine. And wait for the vaccine. And all we could hear about is the vaccine."The injections were developed, but they're different than any prior vaccines and have been losing effectiveness while causing an unacceptable number of serious injuries and deaths. For comparison, in 1976, a fast-tracked injection program against swine flu was halted after an estimated 25 to 32 deaths.7According to McCullough in the video, if a new drug comes on the market and five deaths occur, the standard is to issue a black box warning stating the medication may cause death. With 50 deaths, the product is pulled from the market, he says. Now consider this: The Vaccine Adverse Event Reporting System (VAERS) database showed that — for all vaccines combined before 2020 — there were about 158 total deaths reported per year.By January 22, 2021, there were already 182 deaths reported for COVID-19 injections, with just 27.1 million people vaccinated. This was more than enough to reach the mortality signal of concern to stop the program, McCullough said."We've already crossed the line of concern January 22. And if there was a data safety monitoring board — I know, because I do this work — we would have had an emergency meeting and said, wait a minute, people are dying after the vaccine. We've got to figure out why."8It's standard to have an external critical event committee, an external data safety monitoring board and a human ethics committee for large clinical trials — such as the mass COVID-19 injection program, but these were not put into place."This is something we've never seen in human medicine — a new product introduced and just going full-steam ahead with no check on why people are dying after the vaccine," McCullough said. On two occasions, the CDC and FDA — in March and in June — reviewed the data and said none of the deaths are related to the vaccines. "I think this is malfeasance," he stated.Fast-forward to July 30, 2021, and VAERS data showed 12,366 Americans have died after a COVID0-19 injection.9 In an analysis of COVID-19 vaccine death reports from VAERS, researchers found that 86% of the time, nothing else could have caused the death, and it appears the vaccine was the cause.10The Spike Protein Is Dangerous Your body recognizes the spike protein in COVID-19 jabs as foreign, so it begins to manufacture antibodies to protect you against COVID-19, or so the theory goes. But there's a problem. The spike protein itself is dangerous and known to circulate in your body at least for weeks and more likely months11 — perhaps much longer — after the COVID jab.In your cells, the spike protein damages blood vessels and can lead to the development of blood clots.12 It can go into your brain, adrenal glands, ovaries, heart, skeletal muscles and nerves, causing inflammation, scarring and damage in organs over time. McCullough also believes that the spike protein is present in donated blood, and they've notified the Red Cross and the American Association of Blood Banking.Messenger RNA (mRNA) platforms have been under study for years, in most cases being designed to replace a defective gene, which could potentially be used for cancer or heart failure treatment, for example.In November 2020, however, Pfizer, in a joint venture with Germany-based BioNTech, announced that their mRNA-based injection was "more than 90% effective" in a Phase 3 trial.13 This does not mean that 90% of people who get injected will be protected from COVID-19, as it's based on relative risk reduction (RRR).The absolute

risk reduction (ARR) for the jab is less than 1%. "Although the RRR considers only participants who could benefit from the jab, the absolute risk reduction (ARR), which is the difference between attack rates with and without a jab, considers the whole population. ARRs tend to be ignored because they give a much less impressive effect size than RRRs," researchers wrote in The Lancet Microbe in April 2021.14McCullough believes the mass injection campaign is an incredible violation of human ethics, in part because no one should be pressured, coerced or threatened into using an investigational product.No attempts have been made to present or mitigate risks to the public, such as giving it only to people who really need it — not to low risk groups like children and young people and those who are naturally immune to COVID-19 due to prior infection. "I think this is the most disturbing thing," he said.The Injections Don't Stop COVID-19, Can Be Deadly The CDC's Morbidity and Mortality Weekly Report (MMWR) posted online July 30, 2021, details an outbreak of COVID-19 that occurred in Barnstable County, Massachusetts — 74% of the cases occurred in fully vaccinated people.15Indiscriminate vaccination is driving mutations, as the virus is mutating wildly to evade the injections. Their effectiveness, too, is rapidly waning. A study published in medRxiv, using data from the Mayo Clinic Health System, revealed that during periods of Alpha and Delta variant prevalence, Moderna's injection was 76% effective while Pfizer's effectiveness was only 42%.16A little-known fact is that Moderna's jab has three times the dose of Pfizer's, but, curiously, health officials aren't even discussing this or giving the public updates on which of the three injections work "best." The narrative is simple and straightforward — get an injection, any injection.Yet, as McCullough noted, the virus has mutated, and the vaccines aren't working the way health officials had hoped: "The vaccines don't stop COVID-19, at least not completely, and they're not a shield against mortality."17Similar to VAERS, the U.K. maintains a "Yellow Card" reporting site to report adverse effects to vaccines and medications.18Tess Lawrie, whose company The Evidence-Based Medicine Consultancy has worked with the World Health Organization, analyzed U.K. Yellow Card data and concluded that there's more than enough evidence to pull the injections from the market because they're not safe for human use. The report stated:19"It is now apparent that these products in the blood stream are toxic to humans. An immediate halt to the vaccination programme is required whilst a full and independent safety analysis is undertaken to investigate the full extent of the harms, which the UK Yellow Card data suggest include thromboembolism, multisystem inflammatory disease, immune suppression, autoimmunity and anaphylaxis, as well as Antibody Dependent Enhancement (ADE)."Early Treatment Is Crucial McCullough is trying to get the word out about the importance of early treatment of COVID-19. Early ambulatory therapy with a sequenced-multidrug regimen is supported by available sources of evidence and has a positive benefit-to-risk profile to reduce the risk of hospitalization and death.At 53:40 in the video, you can view McCullough's early treatment regimen, which initially includes a nutraceutical bundle. While you're recovering at home, open your windows and get plenty of fresh air and ventilation in your home.If symptoms persist or worsen, he recommends calling your doctor and demanding monoclonal antibody therapy. The treatment progresses to include anti-infectives like HCQ or ivermectin, antibiotics, steroids and blood thinners.If your doctor refuses to treat COVID-19 in the early stages, find a new one and/or visit a telemedicine clinic that will help, as "the prehospital phase is the time of therapeutic opportunity."📷McCullough is among a growing number of experts who believe COVID-19 injections are making the pandemic worse. They "have an unfavorable

safety profile and are not clinically effective, thus they cannot be generally supported in clinical practice at this time."Logically, this is clear, but McCullough believes we're dealing with a mass psychosis that is preventing people from seeing the light. "The whole world is in a trance," he said, adding:20"Things are getting disturbingly out of control and it's in the context of the virus. It is clear … we are in a very special time in the history of mankind. Whatever is going on, it is the entire world … every human being in the world. It appears to have a program.The program … is happening to promote as much fear, isolation, suffering, hospitalization and death in order to get a needle in every arm, at all costs. That is what's going on, and no one in this room can disagree."

Et pourtant 25 études sur 25 convergent en cas de traitement précoce

Qu’il s’agisse du milieu médical ou du milieu médiatique, le niveau déontologique des procédés n’est pourtant pas la chose la plus surprenante. Le plus surprenant est que cela puisse se produire à un moment où les résultats s’accumulent qui disqualifient cette mise au pas. Ils peuvent être consultés sur le site c19study qui recense tous les essais comparant à un groupe de contrôle les patients traités par l’hydroxychloroquine (ou par d’autres ingrédients). J’ai évidemment vérifié que toutes les études signalées par les médias comme disqualifiant le traitement marseillais étaient bien recensées (Recovery, Solidarity, Discovery, et quelques autres, y compris la méta analyse évoquée plus haut de Fiolet et alii).

Ce site est alimenté en temps réel et sa consultation (le 29 janvier) révélait 195 études recensées. Sur ce total, plus des trois quarts font état d’un résultat positif de l’usage de l’hydroxychloroquine. Si l’on ne considère que les 25 essais qui correspondent à un traitement précoce, tel que recommandé par Didier Raoult (qui a expliqué très tôt la relative inutilité d’un traitement tardif), toutes (oui, toutes !) les études font état d’un effet positif, y compris 5 essais randomisés. Plus spectaculaire encore, les 10 essais qui concentrent l’évaluation sur la mortalité font tous état d’un gain de plus de 50 %.

A ces publications scientifiques on peut opposer des affirmations sans nuance comme celle d’Olivier Véran qui affirmait le 5 novembre dernier que « le traitement n’a pas montré son efficacité » alors qu’à cette date, 19 des 25 études sur le traitement précoce étaient publiées et donc (du moins on l’espère) connues de ses services.

On peut opposer aussi nombre d’affirmations sans nuance, répercutées par les médias sans le moindre souci de vérification tel ce commentaire qui date du 21 janvier, quelques jours après la péripétie de la « lettre d’aveu » et qui éreinte les tenants de la thérapie marseillaise : « Ils sont rigolos parce qu’ils sont restés complètement bloqués sur ça alors que depuis, tous (sic) les essais randomisés vont dans le même sens ainsi que toutes les méta-analyses. A un moment il faut rentrer en 2021, l’HCQ n’est même plus un sujet... ». L’auteur est Nathan Peiffer-Smadja, ancien doctorant de Yasdan Yasdanpanah, assistant chef de clinique à l’hôpital Bichat, coauteur de l’article « Fiolet et alii » et qui écrivait encore un article pour encourager la poursuite des essais sur le Remdesivir le 23 novembre dernier, après donc que son inefficacité et ses effets nocifs aient été signalés par l’OMS.

https://c19study.com/

100% of the 29 early treatment studies report a positive effect (13 statistically signicant in isolation).

Random effects meta-analysis with pooled effects using the most serious outcome reported shows 66% improvement for the 29 early treatment studies (RR 0.34 [0.24-0.49]). Results are similar after exclusion based sensitivity analysis: 67% (RR 0.33 [0.24-0.44]), and after restriction to 20 peer- reviewed studies: 65% (RR 0.35 [0.25-0.47]). Restricting to the 6 RCTs shows 46% improvement (RR 0.54 [0.33-0.86]). Restricting to the 13 mortality results shows 75% lower mortality (RR 0.25 [0.16- 0.40]).

Late treatment is less successful, with only 70% of the 170 studies reporting a positive effect. Very late stage treatment is not effective and may be harmful, especially when using excessive dosages.

The probability that an ineffective treatment generated results as positive as the 251 studies to date is estimated to be 1 in 538 trillion (p = 0.0000000000000019).

87% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0037.

There is substantial evidence of bias towards publishing negative results. 82% of prospective studies report positive effects, and only 72% of retrospective studies do. Studies from North America are 3.2 times more likely to report negative results than studies from the rest of the world combined, p = 0.0000000113.

Negative meta analyses of HCQ generally choose a subset of trials, focusing on late treatment, especially trials with very late treatment and excessive dosages.

While many treatments have some level of ecacy, they do not replace vaccines and other measures to avoid infection. Only 5% of HCQ studies show zero events in the treatment arm.

Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. All practical, effective, and safe means should be used. Not doing so increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage.

All data to reproduce this paper and the sources are in the appendix. See [Ladapo, Prodromos, Risch, Risch (B)] for other meta analyses showing efficacy when HCQ is used early.

Total: 251 studies 3,994 authors 380,038 patients

Positive Effects: 187 studies 2,862 authors 266,059 patients

Early Treatment: 66% improvement RR 0.34 [0.24-0.49]

Late Treatment: 22% improvement RR 0.78 [0.73-0.84]